Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 6, 2006, Pages 875-894

  Martignoni, Marcella ^a   Groothuis, Geny M M ^b   de Kanter, Ruben ^c  

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Animal model; CYP; Cytochrome P450; Drug metabolism; Non rodent; Rodent

Indexed keywords

ARACHIDONIC ACID; BENZODIAZEPINE; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 1B1; CYTOCHROME P450 2A; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DICLOFENAC; DRUG METABOLIZING ENZYME; IBUPROFEN; KETAMINE; PACLITAXEL; PHENYTOIN; PIROXICAM; PROPOFOL; QUINIDINE; RETINOIC ACID; RETINOL; SULFAPHENAZOLE; TAMOXIFEN; TOLBUTAMIDE; UNINDEXED DRUG; XENOBIOTIC AGENT;

BIOTRANSFORMATION; COMPETITIVE INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; LIVER METABOLISM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPECIES CONSERVATION; SPECIES DIFFERENCE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; HAPLORHINI; HUMANS; ISOENZYMES; METABOLIC DETOXICATION, DRUG; MICE; PHARMACEUTICAL PREPARATIONS; RATS; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; RODENTIA;

EID: 33845473315     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.6.875     Document Type: Review

References (220)

1. CASAL M, HASKINS M: Large animal models and gene therapy. Eur. J. Hum. Genet. (2005) 14(3):266-272.
2. POGGESI I: Predicting human pharmacokinetics from preclinical data. Curr. Opin. Drug Discov. Devel. (2004) 7:100-111.
3. DEDRICK RL: Animal scale-up. J. Pharmacokinet. Biopharm. (1973) 1:435-461.
4. BOXENBAUM H: Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. (1982) 10:201-227.
5. BOXENBAUM H: Interspecics pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev. (1984) 15:1071-1121.
6. MAHMOOD I, BALIAN JD: Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci. (1996) 85:411-414.
7. STEVENS JC, SHIPLEY LA, CASHMAN JR, VANDENBRANDEN M, WRIGHTON SA: Comparison of human and rhesus monkey in vitro Phase I and Phase II hepatic drug metabolism activities. Drug Metab. Dispos. (1993) 21:753-760.
8. DAVIES B, MORRIS T: Physiological parameters in laboratory animals and humans. Pharm. Res. (1993) 10:1093-1095.
9. LIN JH: Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. (1995) 23:1008-1021.
10. NELSON DR, KAMATAKI T, WAXMAN DJ et al.: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. (1993) 12:1-51.
11. GONZALEZ FJ: The molecular biology of cytochrome P450s. Pharmacol. Rev. (1988) 40:243-288.
12. PETERS WH, KREMERS PG: Cytochromes P450 in the intestinal mucosa of man. Biochem. Pharmacol. (1989) 38:1535-1538.
13. SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGERICH FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270:414-423.
14. WATTENBERG LW, LEONG JL: Inhibition of the carcinogenic action of benzo(a)pyrene by flavones. Cancer Res. (1970) 30:1922-1925.
15. GELBOIN HV: Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol. Rev. (1980) 60:1107-1166.
16. GOLDSTEIN JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. (2001) 52:349-355.
17. SHEN J, WANG RT, XU YC, WANG LW, WANG XR: Interaction models of CYP1A1, GSTM1 polymorphisms and tobacco smoking in intestinal gastric cancer. World J. Gastroenterol. (2005) 11:6056-6060.
18. CASCORBI I: Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur. J. Clin. Invest. (2003) 33(Suppl. 2):17-22.
19. LAMBA JK, LIN YS, SCHUETZ EG, THUMMEL KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. (2002) 54:1271-1294.
20. YU S, WU L, JIN J et al.: Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation (2006) 81:46-51.
21. MUGFORD CA, KEDDERIS GL: Sex-dependent metabolism of xenobiotics. Drug Metab. Rev. (1998) 30:441-498.
22. DIPPLE A: Formation, metabolism, and mechanism of action of polycyclic aromatic hydrocarbons. Cancer Res. (1983) 43:2422s-2425s.
23. SUGIMURA T, SATO S: Mutagens - carcinogens in foods. Cancer Res. (1983) 43:2415s-2421s.
24. GUENGERICH FP: Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem. Biol. Interact. (1997) 106:161-182.
25. MARTIGNONI M, DE KANTER R, MOSCONE A, GROSSI P, MONSHOUWER M: Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice. Cancer Chemother. Pharmacol. (2005) 55:129-135.
26. LINDELL M, LANG M, LENNERNAS H: Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur. J. Drug Metab. Pharmacokinet. (2003) 28:41-48.
27. SHIMADA T, YAMAZAKI H. MIMURA M et al.: Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. (1996) 24:515-522.
28. HAKKOLA J, PASANEN M, HUKKANEN J et al.: Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. (1996) 51:403-411.
29. CHOUDHARY D, JANSSON I, SCHENKMAN JB, SARFARAZI M, STOILOV I: Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. (2003) 414:91-100.
30. BULLOCK P, PEARCE R, DRAPER A et al.: Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab. Dispos. (1995) 23:736-748.
31. UCHIDA T, KOMORI M, KITADA M, KAMATAKI T: Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P450 from polychlorinated biphenyl-treated beagle dogs. Mol. Pharmacol. (1990) 38:644-651.
32. ZHANG QY, WIKOFF J, DUNBAR D, KAMINSKY L: Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab. Dispos. (1996) 24:322-328.
33. ZHANG QY, DUNBAR D, KAMINSKY LS: Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab. Dispos. (2003) 31:1346-1351.
34. MCDONNELL WM, SCHEIMAN JM, TRABER PG: Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology (1992) 103:1509-1516.
35. ZHANG QY, DUNBAR D, OSTROWSKA A, ZEISLOFT S, YANG J, KAMINSKY LS: Characterization of human small intestinal cytochromes P450. Drug Metab. Dispos. (1999) 27:804-809.
36. PAINE MF, SCHMIEDLIN-REN P, WATKINS PB: Cytochrome P450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab. Dispos. (1999) 27:360-364.
37. STAAL YC, VAN HERWIJNEN MH, VAN SCHOOTEN FJ, VAN DELFT JH: Modulation of gene expression and DNA adduct formation in HepG2 cells by polycyclic aromatic hydrocarbons with different carcinogenic potencies. Carcinogenesis (2006) 27:646-655.
38. SHOU M, KRAUSZ KW, GONZALEZ FJ, GELBOIN HV: Metabolic activation of the potent carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver microsomes. Carcinogenesis (1996) 17:2429-2433.
39. SHIMADA T, MARTIN MV, PRUESS-SCHWARTZ D, MARNETT LJ, GUENGERICH FP: Roles of individual human cytochrome P450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. (1989) 49:6304-6312.
40. GUENGERICH FP, TURVY CG: Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. (1991) 256:1189-1194.
41. ZUBER R, ANZENBACHEROVA E, ANZENBACHER P: Cytochromes P450 and experimental models of drug metabolism. J. Cell Mol. Med. (2002) 6:189-198.
42. SAKUMA T, HIEDA M, IGARASHI T et al.: Molecular cloning and functional analysis of cynomolgus monkey CYP1A2. Biochem. Pharmacol. (1998) 56:131-139.
43. GRAHAM RA, DOWNEY A, MUDRA D et al.: In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab. Dispos. (2002) 30:1206-1213.
44. SHARER JE, SHIPLEY LA, VANDENBRANDEN MR, BINKLEY SN, WRIGHTON SA: Comparisons of Phase I and Phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. (1995) 23:1231-1241.
45. EDWARDS RJ, MURRAY BP, MURRAY S et al.: Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis (1994) 15:829-836.
46. BALDWIN SJ, BLOOMER JC, SMITH GJ, AYRTON AD, CLARKE SE, CHENERY RJ: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica (1995) 25:261-270.
47. OKEY AB: Enzyme induction in the cytochrome P450 system. Pharmacol. Ther. (1990) 45:241-298.
48. MARTIGNONI M, DE KANTER R, GROSSI P, MAHNKE A, SATURNO G, MONSHOUWER M: An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR. Chem. Biol. Interact. (2004) 151:1-11.
49. LAKE BG, MEREDITH C, SCOTT MP, RENWICK AB, PRICE RJ: Use of cultured precision-cut rat lung slices to study the in vitro induction of pulmonary cytochrome P450 forms. Xenobiotica (2003) 33:691-702.
50. ROYMANS D, ANNAERT P, VAN HOUDT J et al.: Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab. Dispos. (2005) 33:1004-1016.
51. DIAZ D, FABRE I, DAUJAT M et al.: Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology (1990) 99:737-747.
52. LU C, LI AP: Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem. Biol. Interact. (2001) 134:271-281.
53. ROST KL, ROOTS I: Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin. Pharmacol. Ther. (1994) 55:402-411.
54. BRANCH RA, ADEDOYIN A, FRYE RF, WILSON JW, ROMKES M: In vivo modulation of CYP enzymes by quinidine and rifampin. Clin. Pharmacol. Ther. (2000) 68:401-411.
55. COULSON M, GIBSON GG, PLANT N, HAMMOND T, GRAHAM M: Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: implications for Leydig cell carcinogenesis. Toxicol. Appl. Pharmacol. (2003) 192:154-163.
56. TOON S, HOPKINS KJ, GARSTANG FM, AARONS L, SEDMAN A, ROWLAND M: Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin. Pharmacol. Ther. (1987) 42:33-41.
57. NEWTON DJ, WANG RW, LU AY: Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. (1995) 23:154-158.
58. SHADDOCK JG, CASCIANO DA: Cryopreservation: a reliable method for long-term storage and culture of isolated non-proliferating rat hepatocytes. J. Tiss. Cult. Meth. (1993) 15:49-54.
59. TAURA K, NAITO E, ISHII Y, MORI MA, OGURI K, YAMADA H: Cytochrome P450 1A1 (CYP1A1) inhibitor alpha-naphthoflavone interferes with UDP-glucuronosyltransferase (UGT) activity in intact but not in permeabilized hepatic microsomes from 3-methylcholanthrene-treated rats: possible involvement of UGT-P450 interactions. Biol. Pharm. Bull. (2004) 27:56-60.
60. SESARDIC D, BOOBIS AR, MURRAY BP et al.: Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. (1990) 29:651-663.
61. BOGAARDS JJ, BERTRAND M, JACKSON P et al.: Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica (2000) 30:1131-1152.
62. KOBAYASHI K, URASHIMA K, SHIMADA N, CHIBA K: Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab. Dispos. (2003) 31:833-836.
63. SUTTER TR, TANG YM, HAYES CL et al.: Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. (1994) 269:13092-13099.
64. MCFADYEN MC, BREEMAN S, PAYNE S et al.: Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem. (1999) 47:1457-1464.
65. TANG YM, CHEN GF, THOMPSON PA, LIN DX, LANG NP, KADLUBAR FF: Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. Drug Metab. Dispos. (1999) 27:274-280.
66. MURRAY GI, TAYLOR MC, MCFADYEN MC et al.: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. (1997) 57:3026-3031.
67. HARRIGAN JA, MCGARRIGLE BP, SUTTER TR, OLSON JR: Tissue specific induction of cytochrome P450 (CYP) 1A1 and 1B1 in rat liver and lung following in vitro (tissue slice) and in vivo exposure to benzo(a)pyrene. Toxicol. In Vitro (2006) 20:426-438.
68. KAMINSKY LS, ZHANG QY: The small intestine as a xenobiotic-metabolizing organ. Drug Metab. Dispos. (2003) 31:1520-1525.
69. UNO S, DALTON TP, DRAGIN N et al.: Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol. Pharmacol. (2006) 69:1103-1114.
70. HONKAKOSKI P, NEGISHI M: The structure, function, and regulation of cytochrome P450 2A enzymes. Drug Metab. Rev. (1997) 29:977-996.
71. YAMAZAKI H, INUI Y, YUN CH, GUENGERICH FP, SHIMADA T: Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis (1992) 13:1789-1794.
72. HE XY, TANG L, WANG SL, CAI QS, WANG JS, HONG JY: Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int. J. Cancer (2006) 118:2665-2671.
73. VON WEYMARN LB, BROWN KM, MURPHY SE: Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J. Pharmacol. Exp. Ther. (2006) 316:295-303.
74. HADUCH A, WOJCIKOWSKI J, DANIEL WA: Effect of short- and long-term treatment with antidepressant drugs on the activity of rat CYP2A in the liver. Pharmacol. Rep. (2005) 57:774-781.
75. ROBOTTOM-FERREIRA AB, AQUINO SR, QUEIROGA R, ALBANO RM, RIBEIRO PINTO LF: Expression of CYP2A3 mRNA and its regulation by 3-methylcholanthrene, pyrazole, and beta-ionone in rat tissues. Braz. J. Med. Biol. Res. (2003) 36:839-844.
76. ALBANO EH, AQUINO J, MODI KJ: An unusual case of eosinophilic granuloma. Laryngoscope (1956) 66:445-448.
77. SU T, DING X: Regulation of the cytochrome P450 2A genes. Toxicol. Appl. Pharmacol. (2004) 199:285-294.
78. LEWIS DF, LAKE BG: Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions. Xenobiotica (2002) 32:547-561.
79. AIDA K, NEGISHI M: Posttranscriptional regulation of coumarin 7-hydroxylase induction by xenobiotics in mouse liver: mRNA stabilization by pyrazole. Biochemistry (1991) 30:8041-8045.
80. KHARASCH ED, HANKINS DC, BAXTER PJ, THUMMEL KE: Single-dose disulfiram does not inhibit CYP2A6 activity. Clin. Pharmacol. Ther. (1998) 64:39-45.
81. CZERWINSKI M, MCLEMORE TL, GELBOIN HV, GONZALEZ FJ: Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res. (1994) 54:1085-1091.
82. XIE W, EVANS RM: Orphan nuclear receptors: the exotics of xenobiotics. J. Biol. Chem. (2001) 276:37739-37742.
83. SRIDAR C, KENT UM, NOTLEY LM, GILLAM EM, HOLLENBERG PF: Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. (2002) 301:945-952.
84. COURT MH, DUAN SX, HESSE LM, VENKATAKRISHNAN K, GREENBLATT DJ: Cytochrome P450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology (2001) 94:110-119.
85. LANG T, KLEIN K, FISCHER J et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 11:399-415.
86. STRESSER DM, KUPFER D: Monospeciftc antipeptide antibody to cytochrome P450 2B6. Drug Metab. Dispos. (1999) 27:517-525.
87. EKINS S, VANDENBRANDEN M, RING BJ et al.: Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. (1998) 286:1253-1259.
88. CODE EL, CRESPI CL, PENMAN BW, GONZALEZ FJ, CHANG TK, WAXMAN DJ: Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. (1997) 25:985-993.
89. SCHMIDT R, BAUMANN F, HANSCHMANN H, GEISSLER F, PREISS R: Gender difference in ifosfamide metabolism by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. (2001) 26:193-200.
90. LAMBA V, LAMBA J, YASUDA K et al.: Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. (2003) 307:906-922.
91. JARUKAMJORN K, SAKUMA T, NEMOTO N: Sexual dimorphic expression of mouse hepatic CYP2B: alterations during development or after hypophysectomy. Biochem. Pharmacol. (2002) 63:2037-2041.
92. WAXMAN DJ: Interactions of hepatic cytochromes P450 with steroid hormones. Regioselectivity and stereospecificity of steroid metabolism and hormonal regulation of rat P450 enzyme expression. Biochem. Pharmacol. (1988) 37:71-84.
93. DE WAZIERS I, CUGNENC PH, YANG CS, LEROUX JP, BEAUNE PH: Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. (1990) 253:387-394.
94. SCHUETZ EG, SCHUETZ JD, MAY B, GUZELIAN PS: Regulation of cytochrome P450b/e and P450p gene expression by growth hormone in adult rat hepatocytes cultured on a reconstituted basement membrane. J. Biol. Chem. (1990) 265:1188-1192.
95. YAMAZOE Y, SHIMADA M, MURAYAMA N, KATO R: Suppression of levels of phenobarbital-inducible rat liver cytochrome P450 by pituitary hormone. J. Biol. Chem. (1987) 262:7423-7428.
96. GRAVES PE, ELHAG GA, CIACCIO PJ, BOURQUE DP, HALPERT JR: cDNA and deduced amino acid sequences of a dog hepatic cytochrome P450IIB responsible for the metabolism of 2,2′,4,4′,5,5′-hexachlorobiphenyl. Arch. Biochem. Biophys. (1990) 281:106-115.
97. GRAHAM MJ, BELL AR, CREWE HK et al.: mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica (2003) 33:225-237.
98. OHMORI S, SHIRAKAWA C, MOTOHASHI K et al.: Purification from liver microsomes from untreated cynomolgus monkeys of cytochrome P450 closely related to human cytochrome P450 2B6. Mol. Pharmacol. (1993) 43:183-190.
99. HONKAKOSKI P, SUEYOSHI T, NEGISHI M: Drug-activated nuclear receptors CAR and PXR. Ann. Med. (2003) 35:172-182.
100. VIGNATI LA, BOGNI A, GROSSI P, MONSHOUWER M: A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a cool to evaluate species-specific CYP3A induction. Toxicology (2004) 199:23-33.
101. STIBOROVA M, BOREK-DOHALSKA L, HODEK P, MRAZ J, FREI E: New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch. Biochem. Biophys. (2002) 403:41-49.
102. LU P, SINGH SB, CARR BA et al.: Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J. Pharmacol. Exp. Ther. (2005) 313:518-528.
103. DOHERTY MM, CHARMAN WN: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. (2002) 41:235-253.
104. ROMKES M, FALETTO MB, BLAISDELL JA, RAUCY JL, GOLDSTEIN JA: Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry (1991) 30:3247-3255.
105. ZAPHIROPOULOS PG: Exon skipping and circular RNA formation in transcripts of the human cytochrome P450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol. Cell. Biol. (1997) 17:2985-2993.
106. KLOSE TS, BLAISDELL JA, GOLDSTEIN JA: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol. (1999) 13:289-295.
107. RAHMAN A, KORZEKWA KR, GROGAN J, GONZALEZ FJ, HARRIS JW: Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. (1994) 54:5543-5546.
108. GOLDSTEIN JA, DE MORAIS SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics (1994) 4:285-299.
109. MCCREA JB, CRIBB A, RUSHMORE T et al.: Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin. Pharmacol. Ther. (1999) 65:348-352.
110. KIDD RS, STRAUGHN AB, MEYER MC, BLAISDELL J, GOLDSTEIN JA, DALTON JT: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics (1999) 9:71-80.
111. LAPPLE F, VON RICHTER O, FROMM MF et al.: Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics (2003) 13:565-575.
112. ANDERSSON T, REGARDH CG, LOU YC, ZHANG Y, DAHL ML, BERTILSSON L: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 2:25-31.
113. SKJELBO E, BROSEN K, HALLAS J, GRAM LF: The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. (1991) 49:18-23.
114. ADEDOYIN A, PRAKASH C, O'SHEA D, BLAIR IA, WILKINSON GR: Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics (1994) 4:27-38.
115. REID JM, KUFFEL MJ, RUBEN SL et al.: Rat and human liver cytochrome P450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin. Cancer Res. (2002) 8:2952-2962.
116. MATSUNAGA T, WATANABE K, YAMAMOTO I, NEGISHI M, GONZALEZ FJ, YOSHIMURA H: cDNA cloning and sequence of CYP2C29 encoding P450 MUT-2, a microsomal aldehyde oxygenase. Biochim. Biophys. Acta (1994) 1184:299-301.
117. DELOZIER TC, TSAO CC, COULTER SJ et al.: CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J. Pharmacol. Exp. Ther. (2004) 310:845-854.
118. WANG H, ZHAO Y, BRADBURY JA et al.: Cloning, expression, and characterization of three new mouse cytochrome P450 enzymes and partial characterization of their fatty acid oxidation activities. Mol. Pharmacol. (2004) 65:1148-1158.
119. TSAO CC, COULTER SJ, CHIEN A et al.: Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio- and stereoselective products. J. Pharmacol. Exp. Ther. (2001) 299:39-47.
120. LUO G, ZELDIN DC, BLAISDELL JA, HODGSON E, GOLDSTEIN JA: Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Arch. Biochem. Biophys. (1998) 357:45-57.
121. TSAO CC, FOLEY J, COULTER SJ, MARONPOT R, ZELDIN DC, GOLDSTEIN JA: CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. Mol. Pharmacol. (2000) 58:279-287.
122. BEDNAR MM, GROSS CE, BALAZY MK et al.: 16(R)-hydroxy-5,8,11,14-eicosatetraenoic acid, a new arachidonate metabolite in human polymorphonuclear leukocytes. Biochem. Pharmacol. (2000) 60:447-455.
123. PERLOFF MD, VON MOLTKE LL, COURT MH, KOTEGAWA T, SHADER RI. GREENBLATT DJ: Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J. Pharmacol. Exp. Ther. (2000) 292:618-628.
124. NEDELCHEVA V, GUT I: P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica (1994) 24:1151-1175.
125. AGRAWAL AK, SHAPIRO BH: Gender, age and dose effects of neonatally administered aspartate on the sexually dimorphic plasma growth hormone profiles regulating expression of the rat sex-dependent hepatic CYP isoforms. Drug Metab. Dispos. (1997) 25:1249-1256.
126. MORGAN ET, MACGEOCH C, GUSTAFSSON JA: Hormonal and developmental regulation of expression of the hepatic microsomal steroid 16 alpha-hydroxylase cytochrome P450 apoprotein in the rat. J. Biol. Chem. (1985) 260:11895-11898.
127. ZHAO X, POLLOCK DM, INSCHO EW, ZELDIN DC, IMIG JD: Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension (2003) 41:709-714.
128. RIEDL AG, WATTS PM, DOUEK DC et al.: Expression and distribution of CYP2C enzymes in rat basal ganglia. Synapse (2000) 38:392-402.
129. LEBLANC GA, WAXMAN DJ: Feminization of rat hepatic P450 expression by cisplatin. Evidence for perturbations in the hormonal regulation of steroid-metabolizing enzymes. J. Biol. Chem. (1988) 263:15732-15739.
130. LEBLANC GA, WAXMAN DJ: Mechanisms of cyclophosphamide action on hepatic P450 expression. Cancer Res. (1990) 50:5720-5726.
131. CHANG TK, WAXMAN DJ: Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res. (1993) 53:2490-2497.
132. SHIMADA M, MURAYAMA N, YAMAUCHI K, YAMAZOE Y, KATO R: Suppression in the expression of a male-specific cytochrome P450, P450-male: difference in the effect of chemical inducers on P450-male mRNA and protein in rat livers. Arch. Biochem. Biophys. (1989) 270:578-587.
133. BLAISDELL J, GOLDSTEIN JA, BAI SA: Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab. Dispos. (1998) 26:278-283.
134. MATSUNAGA T, OHMORI S, ISHIDA M, SAKAMOTO Y, NAKASA H, KITADA M: Molecular cloning of monkey CYP2C43 cDNA and expression in yeast. Drug Metab. Pharmacokinet. (2002) 17:117-124.
135. GERBAL-CHALOIN S, PASCUSSI JM, PICHARD-GARCIA L et al.: Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. (2001) 29:242-251.
136. FERGUSON SS, CHEN Y, LECLUYSE EL, NEGISHI M, GOLDSTEIN JA: Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol. Pharmacol. (2005) 68:747-757.
137. FENG HJ, HUANG SL, WANG W, ZHOU HH: The induction effect of rifampicin on activity of mephenytoin 4-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br. J. Clin. Pharmacol. (1998) 45:27-29.
138. KUNZE KL, WIENKERS LC, THUMMEL KE, TRAGER WF: Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. (1996) 24:414-421.
139. TRANSON C, LEEMANN T, DAYER P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. (1996) 50:209-215.
140. JEPPESEN U, GRAM LF, VISTISEN K, LOFT S, POULSEN HE, BROSEN K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. (1996) 51:73-78.
141. NIWA T, INOUE-YAMAMOTO S, SHIRAGA T, TAKAGI A: Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull. (2005) 28:1813-1816.
142. WALSKY RL, OBACH RS, GAMAN EA, GLEESON JP, PROCTOR WR: Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab. Dispos. (2005) 33:413-418.
143. HIROI T, CHOW T, IMAOKA S, FUNAE Y: Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab. Dispos. (2002) 30:970-976.
144. MADANI S, PAINE MF, LEWIS L. THUMMEL KE, SHEN DD: Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm. Res. (1999) 16:1199-1205.
145. 3H]GBR-12935 binding proteins. Arch. Biochem. Biophys. (1990) 276:424-432.
146. EICHELBAUM M, SPANNBRUCKER N, DENGLER HJ: Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur. J. Clin. Pharmacol. (1979) 16:189-194.
147. MAHGOUB A, IDLE JR, DRING LG, LANCASTER R, SMITH RL: Polymorphic hydroxylation of debrisoquine in man. Lancet (1977) 2:584-586.
148. AGUNDEZ JA: Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab. (2004) 5:211-224.
149. NELSON DR, ZELDIN DC, HOFFMAN SM, MALTAIS LJ, WAIN HM, NEBERT DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics (2004) 14:1-18.
150. BLUME N, LEONARD J, XU ZJ, WATANABE O, REMOTTI H, FISHMAN J: Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells. Arch. Biochem. Biophys. (2000) 381:191-204.
151. NELSON DR, KOYMANS L, KAMATAKI T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6:1-42.
152. VENHORST J, TER LAAK AM, COMMANDEUR JN, FUNAE Y, HIROI T, VERMEULEN NP: Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. J. Med. Chem. (2003) 46:74-86.
153. GONZALEZ FJ, MATSUNAGA T, NAGATA K et al.: Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA (1987) 6:149-161.
154. KOMORI M: A novel P450 expressed at the high level in rat brain. Biochem. Biophys. Res. Commun. (1993) 196:721-728.
155. HIROI T, IMAOKA S, CHOW T, FUNAE Y: Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim. Biophys. Acta (1998) 1380:305-312.
156. HELLMOLD H, LAMB JG, WYSS A. GUSTAFSSON JA, WARNER M: Developmental and endocrine regulation of P450 isoforms in rat breast. Mol. Pharmacol. (1995) 48:630-638.
157. CHOW T, HIROI T, IMAOKA S, CHIBA K, FUNAE Y: Isoform-selective metabolism of mianserin by cytochrome P450 2D. Drug Metab. Dispos. (1999) 27:1200-1204.
158. PAULSON SK, ENGEL L, REITZ B et al.: Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab. Dispos. (1999) 27:1133-1142.
159. SHOU M, NORCROSS R, SANDIG G et al.: Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes P450. Drug Metab. Dispos. (2003) 31:1161-1169.
160. MANKOWSKI DC, LADDISON KJ, CHRISTOPHERSON PA, EKINS S, TWEEDIE DJ, LAWTON MP: Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. Arch. Biochem. Biophys. (1999) 372:189-196.
161. HICHIYA H, KURAMOTO S, YAMAMOTO S et al.: Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19. Biochem. Pharmacol. (2004) 68:165-175.
162. HICHIYA H, TAKEMI C, TSUZUKI D et al.: Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver. Biochem. Pharmacol. (2002) 64:1101-1110.
163. SMITH DA, JONES BC: Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. (1992) 44:2089-2098.
164. CREWE HK, LENNARD MS, TUCKER GT, WOODS FR, HADDOCK RE: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992. Br. J. Clin. Pharmacol. (2004) 58:S744-S747; discussion S748-S750.
165. STROBL GR, VON KRUEDENER S, STOCKIGT J, GUENGERICH FP, WOLFF T: Development of a pharmacophore for inhibition of human liver cytochrome P450 2D6: molecular modeling and inhibition studies. J. Med. Chem. (1993) 36:1136-1145.
166. YAMAMOTO Y, TASAKI T, NAKAMURA A et al.: Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics (1998) 8:73-82.
167. LIEBER CS, DECARLI LM: The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo. J. Pharmacol. Exp. Ther. (1972) 181:279-287.
168. SALASPURO MP, LIEBER CS: Non-uniformity of blood ethanol elimination: its exaggeration after chronic consumption. Ann. Clin. Res. (1978) 10:294-297.
169. LIEBER CS: Cytochrome P4502E1: its physiological and pathological role. Physiol. Rev. (1997) 77:517-544.
170. LIEBER CS: The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab. Rev. (2004) 36:511-529.
171. LOFGREN S, HAGBJORK AL, EKMAN S, FRANSSON-STEEN R, TERELIUS Y: Metabolism of human cytochrome P450 marker substrates in mouse: a strain
172. DAI Y, RASHBA-STEP J, CEDERBAUM AI: Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry (1993) 32:6928-6937.
173. WU D, CEDERBAUM AI: Alcohol, oxidative stress, and free radical damage. Alcohol Res. Health (2003) 27:277-284.
174. HETU C, DUMONT A, JOLY JG: Effect of chronic ethanol administration on bromobenzene liver toxicity in the rat. Toxicol. Appl. Pharmacol. (1983) 67:166-177.
175. SIEGERS CP, HEIDBUCHEL K, YOUNES M: Influence of alcohol, dithiocarb and (+)-catechin on the hepatotoxicity and metabolism of vinylidene chloride in rats. J. Appl. Toxicol. (1983) 3:90-95.
176. TSUTSUMI R, LEO MA, KIM CI et al.: Interaction of ethanol with enflurane metabolism and toxicity: role of P450IIE1. Alcohol. Clin. Exp. Res. (1990) 14:174-179.
177. NOVAK RF, WOODCROFT KJ: The alcohol-inducible form of cytochrome P450 (CYP 2E1): role in toxicology and regulation of expression. Arch. Pharm. Res (2000) 23:267-282.
178. KOMORI M, KIKUCHI O, SAKUMA T, FUNAKI J, KITADA M, KAMATAKI T: Molecular cloning of monkey liver cytochrome P450 cDNAs: similarity of the primary sequences to human cytochromes P450. Biochim. Biophys. Acta (1992) 1171:141-146.
179. OHASHI Y, YAMADA K, TAKEMOTO I, MIZUTANI T, SAEKI K: Inhibition of human cytochrome P450 2E1 by halogenated anilines, phenols, and thiophenols. Biol. Pharm. Bull. (2005) 28:1221-1223.
180. COURT MH, VON MOLTKE LL, SHADER RI, GREENBLATT DJ: Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm. Drug Dispos. (1997) 18:213-226.
181. NEBERT DW, RUSSELL DW: Clinical importance of the cytochromes P450. Lancet (2002) 360:1155-1162.
182. MARILL J, CRESTEIL T, LANOTTE M, CHABOT GG: Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol. Pharmacol. (2000) 58:1341-1348.
183. DRESSER GK, SPENCE JD, BAILEY DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. (2000) 38:41-57.
184. PAINE MF, KHALIGHI M, FISHER JM et al.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. (1997) 283:1552-1562.
185. KOLARS JC, SCHMIEDLIN-REN P, SCHUETZ JD, FANG C, WATKINS PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. (1992) 90:1871-1878.
186. BENET LZ, CUMMINS CL, WU CY: Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. (2003) 4:393-398.
187. WRIGHTON SA, RING BJ, WATKINS PB, VANDENBRANDEN M: Identification of a polymorphically expressed member of the human cytochrome P450III family. Mol. Pharmacol. (1989) 36:97-105.
188. WRIGHTON SA, BRIAN WR, SARI MA et al.: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. (1990) 38:207-213.
189. KUEHL P, ZHANG J, LIN Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27:383-391.
190. KOLARS JC, LOWN KS, SCHMIEDLIN-REN P et al.: CYP3A gene expression in human gut epithelium. Pharmacogenetics (1994) 4:247-259.
191. GELLNER K, EISELT R, HUSTERT E et al.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics (2001) 11:111-121.
192. YANAGIMOTO T, ITOH S, SAWADA M, KAMATAKI T: Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1. Arch. Biochem. Biophys. (1997) 340:215-218.
193. YANAGIMOTO T, ITOH S, MULLER-ENOCH D, KAMATAKI T: Mouse liver cytochrome P450 (P450IIIAM1): its cDNA cloning and inducibility by dexamethasone. Biochim. Biophys. Acta (1992) 1130:329-332.
194. SCHELLENS JH, MALINGRE MM, KRUIJTZER CM et al.: Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J. Pharm. Sci. (2000) 12:103-110.
195. ITOH S, SATOH M, ABE Y, HASHIMOTO H, YANAGIMOTO T, KAMATAKI T: A novel form of mouse cytochrome P450 3A (Cyp3a-16). Its cDNA cloning and expression in fetal liver. Eur. J. Biochem. (1994) 226:877-882.
196. DAI D, BAI R, HODGSON E, ROSE RL: Cloning, sequencing, heterologous expression, and characterization of murine cytochrome P450 3a25*(Cyp3a25) a testosterone 6beta-hydroxylase. J. Biochem. Mol. Toxicol. (2001) 15:90-99.
197. SAKUMA T, TAKAI M, ENDO Y et al.: A novel female-specific member of the CYP3A gene subfamily in the mouse liver. Arch. Biochem. Biophys. (2000) 377:153-162.
198. SAKUMA T, ENDO Y, MASHINO M et al.: Regulation of the expression of two female-predominant CYP3A mRNAs (CYP3A41 and CYP3A44) in mouse liver by sex and growth hormones. Arch. Biochem. Biophys. (2002) 404:234-242.
199. ANAKK S, KALSOTRA A, SHEN Q et al.: Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors. FASEB J. (2003) 17:1736-1738.
200. GALLAGHER EP, KUNZE KL, STAPLETON PL, EATON DL: The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol. Appl. Pharmacol. (1996) 141:595-606.
201. LIU Z, MORTIMER O, SMITH CA, WOLF CR, RANE A: Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. Br. J. Clin. Pharmacol. (1995) 39:77-80.
202. GONZALEZ FJ, NEBERT DW, HARDWICK JP, KASPER CB: Complete cDNA and protein sequence of a pregnenolone 16 alpha-carbonitrile-induced cytochrome P450. A representative of a new gene family. J. Biol. Chem. (1985) 260:7435-7441.
203. GONZALEZ FJ, SONG BJ, HARDWICK JP: Pregnenolone 16 alpha-carbonitrile-inducible P450 gene family: gene conversion and differential regulation. Mol. Cell. Biol. (1986) 6:2969-2976.
204. WANG H, KAWASHIMA H, STROBEL HW: cDNA cloning of a novel CYP3A from rat brain. Biochem. Biophys. Res. Commun. (1996) 221:157-162.
205. STROTKAMP D, ROOS PH, HANSTEIN WG: A novel CYP3 gene from female rats. Biochim. Biophys. Acta (1995) 1260:341-344.
206. KIRITA S, MATSUBARA T: cDNA cloning and characterization of a novel member of steroid-induced cytochrome P450 3A in rats. Arch. Biochem. Biophys. (1993) 307:253-258.
207. NAGATA K, OGINO M, SHIMADA M, MIYATA M, GONZALEZ FJ, YAMAZOE Y: Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6betaB) and characterization of the recombinant protein. Arch. Biochem. Biophys. (1999) 362:242-253.
208. YAMAZOE Y, MURAYAMA N, SHIMADA M et al.: A sex-specific form of cytochrome P450 catalyzing propoxycoumarin O-depropylation and its identity with testosterone 6 beta-hydroxylase in untreated rat livers: reconstitution of the activity with microsomal lipids. J. Biochem. (Tokyo) (1988) 104:785-790.
209. ROBERTSON GR, FARRELL GC, LIDDLE C: Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. Biochem. Biophys. Res. Commun. (1998) 242:57-60.
210. MATSUBARA T, KIM HJ, MIYATA M, SHIMADA M, NAGATA K, YAMAZOE Y: Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J. Pharmacol. Exp. Ther. (2004) 309:1282-1290.
211. GUENGERICH FP: Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem. Biol. Interact. (1997) 106:161-182.
212. SMITH DA: Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab. Rev. (1991) 23:355-373.
213. FRASER DJ, FEYEREISEN R, HARLOW GR, HALPERT JR: Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J. Pharmacol. Exp. Ther. (1997) 283:1425-1432.
214. OHMORI S, HORIE T, GUENGERICH FP, KIUCHI M, KITADA M: Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys. Arch. Biochem. Biophys. (1993) 305:405-413.
215. LEHMANN JM, MCKEE DD, WATSON MA, WILLSON TM, MOORE JT, KLIEWER SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. (1998) 102:1016-1023.
216. LECLUYSE EL: Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem. Biol. Interact. (2001) 134:283-289.
217. DANESHMEND TK, WARNOCK DW: Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet. (1988) 14:13-34.
218. ALBENGRES E, LE LOUET H, TILLEMENT JP: Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. (1998) 18:83-97.
219. LUDDEN TM: Pharmacokinetic interactions of the macrolide antibiotics. Clin. Pharmacokinet. (1985) 10:63-79.
220. KRAHENBUHL S, MENAFOGLIO A, GIOSTRA E, GALLINO A: Serious interaction between mibefradil and tacrolimus. Transplantation (1998) 66:1113-1115.